☰

Surya P. Ayalasomayajula, Ph.D. - Publications

Affiliations: 
2004 University of Nebraska Medical Center, Omaha, NE, United States 
Area:
Pharmaceutical Chemistry, Pharmacy, Pharmacology
Tree Info Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Schuehly U, Ayalasomayajula S, Buchbjerg J, Pal P, Golor G, Prescott MF, Sunkara G, Hinder M, Langenickel TH. Pharmacodynamic interaction between intravenous nitroglycerin and oral sacubitril/valsartan (LCZ696) in healthy subjects. European Journal of Clinical Pharmacology. PMID 29974143 DOI: 10.1007/S00228-018-2509-2  0.644
2018 Ayalasomayajula S, Schuehly U, Pal P, Chen F, Zhou W, Sunkara G, Langenickel TH. Effect of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan on pharmacokinetics and pharmacodynamics of a single-dose of furosemide. British Journal of Clinical Pharmacology. PMID 29318651 DOI: 10.1111/Bcp.13505  0.66
2017 Hsiao HL, Langenickel TH, Petruck J, Kode K, Ayalasomayajula S, Schuehly U, Greeley M, Pal P, Zhou W, Prescott MF, Sunkara G, Rajman I. Evaluation of pharmacokinetic and pharmacodynamic drug-drug interaction of sacubitril/valsartan (LCZ696) and sildenafil in patients with mild-to-moderate hypertension. Clinical Pharmacology and Therapeutics. PMID 28599060 DOI: 10.1002/Cpt.759  0.67
2017 Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics. PMID 28527109 DOI: 10.1007/s40262-017-0558-9  0.621
2017 Ayalasomayajula S, Langenickel T, Pal P, Boggarapu S, Sunkara G. Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor. Clinical Pharmacokinetics. PMID 28417439 DOI: 10.1007/S40262-017-0543-3  0.648
2017 Lin W, Ji T, Einolf H, Ayalasomayajula S, Lin TH, Hanna I, Heimbach T, Breen C, Jarugula V, He H. Evaluation of drug-drug interaction potential between sacubitril/valsartan (LCZ696) and statins using a physiologically-based pharmacokinetic model. Journal of Pharmaceutical Sciences. PMID 28089685 DOI: 10.1016/J.Xphs.2017.01.007  0.358
2016 Ayalasomayajula S, Langenickel TH, Chandra P, Wolfson ED, Albrecht D, Zhou W, Pal P, Rajman I, Sunkara G. Effect of food on the oral bioavailability of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects
. International Journal of Clinical Pharmacology and Therapeutics. PMID 27719743 DOI: 10.5414/CP202604  0.622
2016 Akahori M, Ayalasomayajula S, Langenickel T, Pal P, Zhou W, Sunkara G. Pharmacokinetics After Single Ascending Dose, Food Effect, and Safety of Sacubitril/Valsartan (LCZ696), an Angiotensin Receptor and Neprilysin Inhibitor, in Healthy Japanese Subjects. European Journal of Drug Metabolism and Pharmacokinetics. PMID 27324506 DOI: 10.1007/S13318-016-0354-1  0.659
2016 Ayalasomayajula S, Pan W, Han Y, Yang F, Langenickel T, Pal P, Zhou W, Yuan Y, Rajman I, Sunkara G. Assessment of Drug-Drug Interaction Potential Between Atorvastatin and LCZ696, A Novel Angiotensin Receptor Neprilysin Inhibitor, in Healthy Chinese Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics. PMID 27245340 DOI: 10.1007/S13318-016-0349-Y  0.667
2016 Ayalasomayajula SP, Langenickel TH, Jordaan P, Zhou W, Chandra P, Albrecht D, Pal P, Rajman I, Sunkara G. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. European Journal of Clinical Pharmacology. PMID 27230850 DOI: 10.1007/S00228-016-2072-7  0.634
2016 Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, Chandra P, Ayalasomayajula S, Prescott MF, Pal P, Langenickel TH, Jordaan P, Rajman I. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction. Cardiovascular Therapeutics. PMID 26990595 DOI: 10.1111/1755-5922.12183  0.406
2016 Han Y, Ayalasomayajula S, Pan W, Yang F, Yuan Y, Langenickel T, Hinder M, Kalluri S, Pal P, Sunkara G. Pharmacokinetics, Safety and Tolerability of Sacubitril/Valsartan (LCZ696) After Single-Dose Administration in Healthy Chinese Subjects. European Journal of Drug Metabolism and Pharmacokinetics. PMID 26961539 DOI: 10.1007/S13318-016-0328-3  0.677
2015 Langenickel TH, Tsubouchi C, Ayalasomayajula S, Pal P, Valentin MA, Hinder M, Jhee S, Gevorkyan H, Rajman I. The effect of LCZ696 on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. British Journal of Clinical Pharmacology. PMID 26663387 DOI: 10.1111/Bcp.12861  0.33
2015 Ayalasomayajula SP, Meyers CD, Yu J, Kagan M, Matott R, Pal P, Majumdar T, Su Z, Crissey A, Rebello S, Sunkara G, Chen J. Evaluation of food effect on the oral bioavailability of pradigastat, a diacylglycerol acyltransferase 1 inhibitor. Biopharmaceutics & Drug Disposition. PMID 25963481 DOI: 10.1002/Bdd.1958  0.647
2015 Ayalasomayajula S, Meyers D, Koo P, Salunke A, Majumdar T, Rebello S, Sunkara G, Chen J. Assessment of pharmacokinetic drug-drug interaction between pradigastat and acetaminophen in healthy subjects. European Journal of Clinical Pharmacology. 71: 425-32. PMID 25724644 DOI: 10.1007/S00228-015-1822-2  0.647
2015 Ayalasomayajula S, Jordaan P, MBChB, Pal P, Ch P, ra, Albrecht D, Langenickel T, Rajman I, Sunkara G. Assessment of Drug Interaction Potential between LCZ696, an Angiotensin Receptor Neprilysin Inhibitor, and Digoxin or Warfa rin Clinical Pharmacology & Biopharmaceutics. 2015. DOI: 10.4172/2167-065X.1000147  0.679
2014 Sunkara G, Jiang X, Reynolds C, Serra D, Zhang Y, Ligueros-Saylan M, Ayalasomayajula S, Winter S, Jarugula V. Effect of food on the oral bioavailability of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide fixed dose combination tablets in healthy subjects. Clinical Pharmacology in Drug Development. 3: 487-92. PMID 27129123 DOI: 10.1002/Cpdd.131  0.65
2011 Bhad P, Ayalasomayajula S, Karan R, Leon S, Riviere GJ, Sunkara G, Jarugula V. Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. Journal of Clinical Pharmacology. 51: 933-42. PMID 20852001 DOI: 10.1177/0091270010376963  0.651
2010 Sunkara G, Ayalasomayajula SP, DeRuiter J, Kompella UB. Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor. Brain Research Bulletin. 81: 327-32. PMID 19761819 DOI: 10.1016/J.Brainresbull.2009.09.001  0.725
2009 Ayalasomayajula SP, Ashton P, Kompella UB. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM). Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association For Ocular Pharmacology and Therapeutics. 25: 97-103. PMID 19284324 DOI: 10.1089/Jop.2008.0090  0.584
2008 Ayalasomayajula S, Yeh C, Vaidyanathan S, Flannery B, Dieterich HA, Howard D, Bedigian MP, Dole WP. Effects of aliskiren, a direct Renin inhibitor, on cardiac repolarization and conduction in healthy subjects. The Journal of Clinical Pharmacology. 48: 799-811. PMID 18490495 DOI: 10.1177/0091270008319330  0.351
2008 Ayalasomayajula S, Tchaloyan S, Yeh C, Bizot M, Dieterich HA, Howard D, Dole WP. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects Current Medical Research and Opinion. 24: 717-726. PMID 18234150 DOI: 10.1185/030079908X260934  0.344
2007 Ayalasomayajula SP, Dole K, He YL, Ligueros-Saylan M, Wang Y, Campestrini J, Humbert H, Sunkara G. Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects. Current Medical Research and Opinion. 23: 2913-20. PMID 17931461 DOI: 10.1185/030079907X233296  0.677
2007 Ayalasomayajula SP, Vaidyanathan S, Kemp C, Prasad P, Balch A, Dole WP. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin. Journal of Clinical Pharmacology. 47: 613-9. PMID 17442686 DOI: 10.1177/0091270006299138  0.354
2006 Amrite AC, Ayalasomayajula SP, Cheruvu NP, Kompella UB. Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. Investigative Ophthalmology & Visual Science. 47: 1149-60. PMID 16505053 DOI: 10.1167/Iovs.05-0531  0.779
2006 AYALASOMAYAJULA S, VAIDYANATHAN S, KEMP C, NAGANUMA T, LEON S, PRASAD P. PII-48Effect of clopidogrel (Plavix®) on the pharmacokinetics of fluvastatin (Lescol® XL) Clinical Pharmacology & Therapeutics. 79: P48-P48. DOI: 10.1016/J.Clpt.2005.12.173  0.336
2005 Bandi N, Ayalasomayajula SP, Dhanda DS, Iwakawa J, Cheng PW, Kompella UB. Intratracheal budesonide-poly(lactide-co-glycolide) microparticles reduce oxidative stress, VEGF expression, and vascular leakage in a benzo(a)pyrene-fed mouse model. The Journal of Pharmacy and Pharmacology. 57: 851-60. PMID 15969944 DOI: 10.1211/0022357056334  0.745
2005 Ayalasomayajula SP, Kompella UB. Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. European Journal of Pharmacology. 511: 191-8. PMID 15792788 DOI: 10.1016/J.Ejphar.2005.02.019  0.649
2004 Ayalasomayajula SP, Kompella UB. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharmaceutical Research. 21: 1797-804. PMID 15553225 DOI: 10.1023/B:Pham.0000045231.51924.E8  0.656
2004 Ayalasomayajula SP, Amrite AC, Kompella UB. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. European Journal of Pharmacology. 498: 275-8. PMID 15364005 DOI: 10.1016/J.Ejphar.2004.07.046  0.767
2004 Sunkara G, Ayalasomayajula SP, Rao CS, Vennerstrom JL, DeRuiter J, Kompella UB. Systemic and ocular pharmacokinetics of N-4-benzoylaminophenylsulfonylglycine (BAPSG), a novel aldose reductase inhibitor. The Journal of Pharmacy and Pharmacology. 56: 351-8. PMID 15025860 DOI: 10.1211/0022357022908  0.728
2003 Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. The Journal of Pharmacy and Pharmacology. 55: 1199-206. PMID 14604462 DOI: 10.1211/0022357021701  0.76
2003 Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Investigative Ophthalmology & Visual Science. 44: 1192-201. PMID 12601049 DOI: 10.1167/Iovs.02-0791  0.764
2003 Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. European Journal of Pharmacology. 458: 283-9. PMID 12504784 DOI: 10.1016/S0014-2999(02)02793-0  0.658
2002 Ayalasomayajula SP, Kompella UB. Induction of vascular endothelial growth factor by 4-hydroxynonenal and its prevention by glutathione precursors in retinal pigment epithelial cells. European Journal of Pharmacology. 449: 213-20. PMID 12167462 DOI: 10.1016/S0014-2999(02)02043-5  0.6
2002 Aukunuru JV, Sunkara G, Ayalasomayajula SP, DeRuiter J, Clark RC, Kompella UB. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications. Pharmaceutical Research. 19: 278-85. PMID 11934234 DOI: 10.1023/A:1014438800893  0.731
2000 Ayalasomayajula SP, Kompella UB. Drug efflux pumps: challenges and opportunities. 14-18 November 1999, New Orleans, LA, USA. Idrugs : the Investigational Drugs Journal. 3: 148-9. PMID 16107925  0.505
Show low-probability matches.